Residency · Residency · Neurology

Cerebral Venous Sinus Thrombosis

Overview

Cerebral venous sinus thrombosis (CVST) is an uncommon cause of stroke that predominantly affects young adults and women. Its presentation is notoriously variable, ranging from isolated headache to seizures, focal neurological deficits, encephalopathy, or papilledema. The cornerstone of treatment is anticoagulation, which is initiated even when hemorrhagic infarction is present. With appropriate treatment, the prognosis is generally favorable, with approximately 80% of patients achieving functional independence.

Epidemiology and Risk Factors

The incidence of CVST is estimated at 3-4 per million per year, though it is likely underdiagnosed. There is a 3:1 female predominance, with a median age of 30-40 years. Prothrombotic states represent the most important risk category: oral contraceptive use is the most common acquired risk factor, followed by pregnancy and the puerperium, factor V Leiden mutation, prothrombin G20210A mutation, protein C, S, or antithrombin deficiency, antiphospholipid syndrome, and hyperhomocysteinemia. Infectious causes include otitis media and mastoiditis (affecting the lateral sinus), sinusitis (affecting the cavernous sinus or superior sagittal sinus), and meningitis. Inflammatory and autoimmune conditions associated with CVST include Behcet disease, systemic lupus erythematosus, inflammatory bowel disease, and sarcoidosis. Hematologic disorders such as polycythemia vera, essential thrombocythemia, paroxysmal nocturnal hemoglobinuria, and sickle cell disease also confer risk. Mechanical and other causes include head trauma, neurosurgery, lumbar puncture, dehydration, and malignancy. COVID-19 infection has been associated with increased CVST risk, particularly through vaccine-induced immune thrombocytopenia and thrombosis (VITT). No identifiable cause is found in approximately 15% of cases.

Anatomy of the Cerebral Venous System

The superior sagittal sinus (SSS) drains the superior cerebral veins, and its thrombosis causes bilateral parasagittal edema or infarction. The transverse sinus is the most commonly thrombosed sinus; it drains into the sigmoid sinus and then the internal jugular vein. The sigmoid sinus is the continuation of the transverse sinus and is particularly associated with mastoiditis. The straight sinus drains the deep cerebral veins, including the internal cerebral veins and the great vein of Galen; its thrombosis causes bilateral thalamic and basal ganglia injury. The cavernous sinus drains the face and orbits, and its thrombosis produces a distinctive syndrome of proptosis, chemosis, and ophthalmoplegia (involving CN III, IV, and VI) with V1/V2 sensory loss. Isolated cortical vein thrombosis can cause focal deficits and seizures without sinus involvement. Unlike arterial territories, venous infarcts often do not respect arterial vascular boundaries, which is an important diagnostic clue.

Clinical Presentation

Headache

Headache is the most common symptom, occurring in approximately 90% of patients. It is often progressive over days to weeks and may mimic idiopathic intracranial hypertension with a diffuse quality that worsens with Valsalva and is accompanied by papilledema. Thunderclap headache occurs in about 10% of cases and can mimic subarachnoid hemorrhage. In approximately 25% of cases, headache is the sole presenting feature without any focal signs.

Seizures

Seizures occur in approximately 40% of CVST patients, a rate much higher than in arterial stroke. They are often focal with secondary generalization and may be the presenting symptom. Status epilepticus is possible.

Focal Neurological Deficits

The pattern of deficits depends on the sinus and brain regions affected. SSS thrombosis characteristically produces bilateral leg weakness from parasagittal cortex involvement. Transverse sinus thrombosis can produce aphasia or spatial neglect through temporal lobe involvement. Deep venous thrombosis leads to bilateral thalamic involvement, presenting with coma, confusion, or vertical gaze palsy.

Encephalopathy

Diffuse cerebral edema from impaired venous drainage can produce confusion, obtundation, or coma. This is particularly common with extensive thrombosis or deep venous involvement.

Papilledema

Elevated intracranial pressure results from impaired CSF absorption at the arachnoid granulations. Papilledema is bilateral and may cause transient visual obscurations.

Diagnosis

CT Head (Non-Contrast)

Non-contrast CT may show a hyperdense sinus (the dense triangle sign or cord sign), a hemorrhagic infarct not conforming to an arterial territory, or cerebral edema. However, CT is normal in up to 30% of cases. On contrast-enhanced CT, the empty delta sign represents a filling defect in the posterior SSS.

CT Venography (CTV) or MR Venography (MRV)

CTV offers high sensitivity and specificity, is readily available, and is the preferred study in the acute setting. MRV, performed with time-of-flight (TOF) or contrast enhancement, is useful for follow-up, though clinicians must be aware that flow gaps on TOF sequences can mimic thrombosis. MRI with T2* sequences (SWI or GRE) can show thrombus directly as blooming artifact within the affected sinus. On T1-weighted MRI, thrombus appears hyperintense in the subacute phase.

D-Dimer

D-dimer is elevated in most cases of CVST, with sensitivity of approximately 94%. However, a normal D-dimer has only modest negative predictive value and cannot definitively exclude CVST when clinical suspicion is high. It is most useful in low-probability cases, such as patients with isolated headache and no risk factors.

Lumbar Puncture

Opening pressure is elevated (above 25 cmH2O) in approximately 80% of cases. CSF may show elevated protein, pleocytosis, or red blood cells. Lumbar puncture can rule out infectious meningitis when indicated, but should be performed only after imaging has excluded significant mass effect.

Treatment

Anticoagulation

Heparin (either unfractionated or low-molecular-weight) should be initiated immediately upon diagnosis, even in the presence of hemorrhagic infarction. The TO-ACT trial (2022) confirmed the safety and suggested comparable efficacy of LMWH compared to UFH, making LMWH preferred for most patients. The rationale for anticoagulating despite hemorrhage is that venous hypertension is the underlying cause of the bleeding; anticoagulation treats the root problem and prevents thrombus propagation. Patients are then transitioned to oral anticoagulation with warfarin (target INR 2-3) after the acute phase. Direct oral anticoagulants (DOACs) are emerging as a reasonable alternative based on the RE-SPECT CVT trial and the ACTION-CVT observational study, though they are not yet universally guideline-endorsed.

Duration of Anticoagulation

For provoked CVST with a transient risk factor, 3-6 months of anticoagulation is standard. Unprovoked CVST or CVST associated with mild thrombophilia warrants 6-12 months. Patients with severe thrombophilia or recurrent venous thromboembolism require indefinite anticoagulation. Repeat imaging with MRV at 3-6 months assesses recanalization.

Endovascular Therapy

Endovascular intervention is reserved for patients who deteriorate despite adequate anticoagulation. Options include catheter-directed thrombolysis and mechanical thrombectomy. No randomized controlled trial has demonstrated clear benefit, and the TO-ACT trial did not show benefit for endovascular therapy over anticoagulation alone. It should be considered only in severe, life-threatening cases with mass effect or impending herniation.

Management of Elevated ICP

Acetazolamide is used for persistent headache or papilledema from elevated intracranial pressure. Therapeutic lumbar puncture is appropriate when vision is threatened. A ventriculoperitoneal shunt may be necessary in refractory cases. Corticosteroids should be avoided as there is no evidence of benefit and they may increase thrombotic risk.

Seizure Management

Acute seizures are treated with standard antiseizure medications. Prophylactic ASMs may be considered in patients with cortical involvement or hemorrhagic infarction. The duration of ASM therapy is typically 3-12 months if no recurrent seizures occur.

Special Populations

Pregnancy and Postpartum

CVST occurs in approximately 12 per 100,000 deliveries. LMWH is the treatment of choice because it does not cross the placenta. Warfarin is contraindicated in the first trimester but can be used postpartum. LMWH can be continued through delivery with planned interruption around the time of labor.

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

VITT is a rare complication of adenoviral vector COVID-19 vaccines that presents with CVST in combination with thrombocytopenia and anti-PF4 antibodies. Treatment requires a non-heparin anticoagulant (argatroban, fondaparinux, or a DOAC) combined with IVIG. Heparin must be avoided because it can worsen the condition through a mechanism similar to heparin-induced thrombocytopenia.

<image>An anatomical diagram of the cerebral venous sinuses in lateral and superior views, showing the superior sagittal sinus, inferior sagittal sinus, straight sinus, transverse sinuses, sigmoid sinuses, cavernous sinuses, and major cortical and deep cerebral veins (vein of Labbe, vein of Trolard, internal cerebral veins, great vein of Galen). Each sinus is color-coded with annotations indicating the typical clinical syndrome when thrombosed: SSS (bilateral parasagittal infarcts, leg weakness), transverse (temporal lobe involvement, aphasia), deep veins (bilateral thalamic injury, coma), and cavernous (proptosis, ophthalmoplegia).</image>

<image>A diagnostic imaging panel for CVST. Panel A: non-contrast CT showing the dense triangle sign in the superior sagittal sinus and a hemorrhagic venous infarct in the left frontal-parietal region not conforming to an arterial territory. Panel B: contrast-enhanced CT showing the empty delta sign. Panel C: CT venography with a filling defect in the left transverse sinus. Panel D: MR venography (time-of-flight) showing absent flow signal in the left transverse and sigmoid sinuses compared to the normal right side. Panel E: MRI T1-weighted showing hyperintense thrombus in the subacute phase within the superior sagittal sinus.</image>

<image>A treatment algorithm for CVST. Starting with confirmed diagnosis, the flowchart shows: (1) initiate anticoagulation (LMWH preferred) regardless of hemorrhagic infarction, (2) manage seizures if present, (3) assess for elevated ICP and treat (acetazolamide, therapeutic LP), (4) monitor neurologically and with repeat imaging, (5) if deteriorating despite anticoagulation -> consider endovascular therapy, (6) transition to oral anticoagulation (warfarin or DOAC) with duration determined by provoked vs unprovoked vs thrombophilia. A special branch addresses VITT (non-heparin anticoagulant + IVIG). Follow-up MRV at 3-6 months is noted.</image>

Clinical Pearls

CVST should be considered in any young patient with progressive headache, seizures, or focal deficits, particularly in the presence of risk factors such as oral contraceptive use, pregnancy, or a known prothrombotic state. Hemorrhagic venous infarcts that do not respect arterial vascular territories are a strong diagnostic clue. The decision to anticoagulate even with hemorrhagic infarction is counterintuitive but well-supported by evidence; the hemorrhage results from venous congestion, and anticoagulation addresses the underlying mechanism. D-dimer is a useful screening test but cannot reliably exclude CVST when clinical suspicion is high. Seizures are much more common in CVST (approximately 40%) than in arterial stroke (5-10%). Deep venous thrombosis involving the straight sinus and internal cerebral veins, with bilateral thalamic involvement, carries the worst prognosis. In the setting of VITT, heparin must be avoided in favor of non-heparin anticoagulants combined with IVIG.

References

• Ferro JM, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis. Eur Stroke J. 2017;2(3):195-221.
• Coutinho JM, et al. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375-3377.
• Coutinho JM, et al. Thrombolysis or anticoagulation for cerebral venous thrombosis (TO-ACT). Lancet Neurol. 2022;21(3):226-235.
• Silvis SM, et al. Cerebral venous thrombosis. Nat Rev Neurol. 2017;13(9):555-565.
• Saposnik G, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals. Stroke. 2011;42(4):1158-1192.

Read this lecture as Markdown